Methods of detecting and treating airway inflammatory diseases
AssigneeNational Jewish Health
InventorsMax SEIBOLD, Jamie EVERMAN
Life of this patent
Estimating the term…
Abstract
The present invention is related to novel methods for identifying and/or diagnosing and/or treating a population of subjects that are at risk for developing and/or have an inflammatory disease of the airways, including type 2 cytokine-driven airway inflammation.
Claims29
A method of identifying a subject having or at risk of having a type-2 (Th2) airway inflammatory disease, the method comprising:
- a. obtaining a blood sample from the subject;
- b. determining the level of one or more interleukin-13 (IL-13) induced proteins in the sample;
- and
- c. comparing the level of the one or more IL-13 induced proteins in the sample to a control sample wherein the presence and/or higher level of the one or more IL-13 induced proteins as compared to the control sample identifies the subject as having or at risk of having a type-2 airway inflammatory disease.
A method of diagnosing and treating a type-2 (Th2) airway inflammatory disease, the method comprising:
- a. obtaining a blood sample from the subject;
- b. determining the level of one or more IL-13 induced proteins in the sample;
- c. comparing the level of the one or more IL-13 induced proteins in the sample to a control sample, wherein the presence and/or a higher level of the one or more IL-13 induced proteins as compared to the control sample identifies the subject as having a type-2 airway inflammatory disease;
- and
- d. administering an effective amount of an inhaled corticosteroid and/or Th2 pathway inhibitor.
A method to endotype a subject as having Th2-high asthma, the method comprising:
- a. obtaining a blood sample from the subject;
- b. determining the level of one or more IL-13 induced proteins in the sample;
- and
- c. comparing the level of the one or more IL-13 induced proteins in the sample to a control sample wherein the presence and/or higher level of the one or more IL-13 induced proteins as compared to the control sample identifies the subject as having Th2-high asthma.
(canceled)
A method to predict the response of a subject to treatment with a Th2 pathway inhibitor, who has, or who is at risk of developing a Th2 airway inflammatory disease, the method comprising
- a. obtaining a blood sample from the subject;
- b. determining the level of one or more interleukin-13 (IL-13) induced proteins in the sample;
- c. comparing the level of the one or more IL-13 induced proteins in the sample to a control sample wherein the presence and/or higher level of the one or more IL-13 induced proteins as compared to the control sample identifies the subject as having or at risk of having a Th2 airway inflammatory disease responsive to treatment with a Th2 pathway inhibitor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method to detect one or more IL-13 induced proteins and/or small molecules in a sample from a subject comprising:
- a. culturing airway epithelial cells obtained from the subject;
- b. differentiating the cells at air-liquid interface (ALI);
- c. treating cells with either bovine serum albumin (BSA) or IL-13 daily;
- d. washing the treated cells;
- and
- e. detecting IL-13 induced proteins and/or small molecules by mass spectrometry.
(canceled)
(canceled)
Dependencies are inferred from the claim text.